The costimulatory effects of CD27 on T lymphocyte effector function and memory formation has been confined to evaluations in mouse models, in vitro human cell culture systems and clinical observations.
Introduction

The genetic engineering of T cells to express chimeric antigen receptors (CAR)
couple the high affinity binding of antibodies with the signaling domains of the T cell receptor (TCR) CD3ζ chain for antigen-specified triggering of T cell activation similar to the endogenous TCR with 10% heat inactivated fetal bovine serum (FBS), 100 U/ml penicillin, 100 ug/ml streptomycin sulfate, 10-mM HEPES), and stimulated with anti-CD3 and anti-CD28 mAbs coated beads (Invitrogen)
as described 27 . 12-24hr after activation, cells were transduced with lentiviral vectors at MOI of ~5-10.
CD4+ and CD8+ T cells used for in vivo experiments were mixed at 1:1 ratio, activated, and transduced.
Human recombinant interleukin-2 (IL-2; Novartis) was added every other day to 50 IU/ml final concentration and a 0.5-1x10 6 cells/ml cell density was maintained. Once T cells rested down, ~14 days after stimulation and determined by decreased growth kinetics and cell size (~250 femtoliters) using signaling moiety alone (FR-z) or in tandem with the CD27 intracellular signaling motif (FR-27z; Figure 1A ). A CD19-specific CAR containing CD3ζ and CD27 signaling motifs in tandem (CD19-27z) was constructed to control for antigen specificity. CAR constructs were subcloned into the pELNS lentiviral vector where transgene expression is driven off the EF-1α promoter. . To test and compare CD27 to these domains, we generated MOv19-based FR-28z and Figures S6,7) . Further, cognate antigen recognition reinforces the persistence of
CAR-T cells in vivo, since mice that received FR-z CAR-T cells had increased CAR+ T cell counts
to mice in CD19-27z CAR-T (P=0.017) or gfp T cell groups, which had little to no detectable persistence of CAR+ T cells, respectively (Supplemental Figure 6) .
Notably, surface CAR expression was better maintained in the FR-28z group (Figure 5F ), compared to other groups (p<0.01), consistent with prior findings 12 . As such, the absolute number of circulating CAR+ T cells in tumor-bearing mice administered FR-27z, FR-28z and FR-BBz were not statistically different (p>0.05), but higher than that observed in mice receiving first generation FR-z
CAR-T cells (Supplemental Figures S5B).
For .
The intracytoplasmic domain of CD27 used in our study and triggered naturally by CD70 ligation mediates pro-survival effects through interaction with TRAF2 and activation of Jun kinase and NF-κB, which is required for optimal effector/memory CD8+ T cell generation 46 . The mechanism by which CD27 prevents activation-induced cell death and promotes T cell survival includes the upregulation of anti-apoptotic Bcl-X L protein expression 41 and resistance to Fas mediated apoptosis 47 . After stimulation in vitro, increased Bcl-X L protein expression has been observed in T cells engineered to express a CD70-specific, chimeric CD27-CD3z CAR consisting of the both the extracellular and intracellular CD27 domains 40 . Consistent with this finding, we observed increased expression of Bcl-X L protein in Our results support the notion that human T cells that are enabled to receive CD27 costimulatory signals in conjunction with CD3ζ signaling receive amplified anti-apoptotic signals that facilitate enhanced effector activity and better survival in vivo, assuring the generation of stable human T cell memory. The addition of costimulatory domains, particularly the intracellular domains of CD28, and the tumor necrosis factor receptor family members, CD134 and 4-1BB (CD137), can also significantly augment the ability of these receptors to stimulate cytokine secretion, support T cell survival and enhance antitumor efficacy in preclinical animal models using both solid tumors and leukemia that lack the expression of their cognate costimulatory ligands [5] [6] [7] [8] [9] [10] [11] [12] . Results of comparative in vivo studies of
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another member of the TNFR superfamily enhances T cell antitumor activity and persistence. In contrast, CD28, which can support enhanced antitumor activity, does not support robust numerical T cell persistence. Rather, CD28 supports stable surface CAR expression, which may be attributed in part to the inclusion of its transmembrane region in the CAR construct, as suggested previously 12 . Notably, each of these costimulatory molecules can dramatically improve the activity and overcomes the limitations of first generation CAR approaches by improving the persistence of transferred T cells in vivo. These results rationalize the clinical investigation of CD27 costimulated CAR-T cell therapy in combination with lymphodepleting pre-conditioning for the treatment of cancer. Our data further suggest that the combination of CD27 or CD137 endodomains with the CD28 signaling domain may be more effective than CD27, CD137 or CD28 alone.
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